| Crude | Adjustedb | Crude | Adjustedb | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | 50th | Diff | (CI 95%) | 50th | Diff | (CI 95%) | 90th | Diff | (CI 95%) | 90th | Diff | (CI 95%) | |
| Index consultation assessment | |||||||||||||
| No suspicion | 127 | 83 | ref | 92 | ref | 230 | ref | 151 | ref | ||||
| Suspected cancer | 197 | 31 | –52 | (–66 to –38) | 32 | –60 | (–69 to –51) | 218 | –12 | (–22 to –1) | 151 | 0 | (–11 to 10) |
| Suspected other serious disease | 92 | 36 | –47 | (–53 to –41) | 42 | –50 | (–66 to –34) | 199 | –31 | (–39 to –22) | 116 | –35 | (–39 to –31) |
| Cancer types | |||||||||||||
| Colorectal | 82 | 54 | ref | 53 | ref | 238 | ref | 234 | ref | ||||
| Breast | 193 | 45 | –9 | (–17 to –1) | 43 | –10 | (–36 to 15) | 209 | –29 | (–39 to –19) | 219 | –15 | (–30 to 0) |
| Lung | 54 | 52 | –2 | (–10 to 7) | 53 | 0 | (–13 to 14) | 185 | –53 | (–59 to –46) | 174 | –60 | (–78 to –43) |
| Melanoma | 46 | 49 | –5 | (–10 to 0) | 47 | –6 | (–24 to 12) | 347 | 109 | (102 to 115) | 281 | 47 | (32 to 62) |
| Bladder | 19 | 30 | –24 | (–30 to –17) | 31 | –22 | (–41 to –4) | 175 | –63 | (–68 to –57) | 137 | –97 | (–112 to –82) |
| Endometrial | 16 | 44 | –10 | (–15 to –5) | 44 | –9 | (–21 to 2) | 155 | –83 | (–88 to –77) | 153 | –81 | (–97 to –64) |
| Ovarian | 6 | 68 | 14 | (9 to 19) | 69 | 16 | (–11 to 43) | 173 | –65 | (–70 to –60) | 237 | 3 | (–18 to 23) |
| GP actionsc | |||||||||||||
| Watchful waiting | 49 | 100 | 56 | (44 to 67) | 74 | 37 | (32 to 43) | 283 | 72 | (60 to 84) | 226 | 25 | (15 to 35) |
| Await follow-upd | 29 | 78 | 26 | (19 to 32) | 62 | 20 | (6 to 33) | 185 | –14 | (–23 to –6) | 98 | –20 | (–25 to –14) |
| Tests in general practicee | 128 | 53 | 7 | (–7 to 20) | 52 | 10 | (–1 to 21) | 214 | –1 | (–12 to 11) | 169 | 25 | (19 to 30) |
| Confer with specialistf | 41 | 36 | –13 | (–17 to –9) | 37 | –8 | (–21 to 5) | 140 | –77 | (–89 to –65) | 134 | –61 | (–75 to –47) |
| Referral | 255 | 14 | –24 | (–34 to –14) | 14 | –16 | (–27 to –5) | 201 | –8 | (–20 to 4) | 126 | –18 | (–24 to –12) |
| Referral modality | |||||||||||||
| Cancer patient pathway | 123 | 23 | ref | 19 | ref | 181 | ref | 204 | ref | ||||
| Specialist | 54 | 64 | 41 | (33 to 49) | 52 | 33 | (–22 to 88) | 209 | 28 | (21 to 36) | 243 | 39 | (3 to 76) |
| Imaging or other | 78 | 54 | 31 | (27 to 36) | 55 | 36 | (13 to 58) | 279 | 98 | (89 to 106) | 231 | 27 | (20 to 34) |
aPseudo-centiles were used for reporting of 50th and 90th percentile diagnostic interval length of references; for non-references the total diagnostic interval lengths are calculated from adding the point estimate to the reference value. bIndex consultation assessment adjusted for sex, age, follow-up status, comorbidity, and educational level. Cancer types adjusted for age and educational level. GP actions and referral modality were adjusted for age, sex, comorbidity level, follow-up status, and educational level. cSeparate analyses were conducted for each action with the reference group comprising all patients without that particular action (n = 416). dAmong patients in active follow-up (n = 235). eSuch as blood tests, urinalysis, spirometry. fNon-referral contact by phone or letter to specialist. Bold indicates statistical significance, P≤0.05. Diff = difference.